**Interface Therapeutics Inc.** was founded in 2014 by [[Ryan Jones]] and [[Mitchell Jones]], and later acquired by [[Biora Therapeutics]] in 2015. According to Mitchell Jones, the company "developed a novel platform sampling technology and multi-omics approach to discover and develop GI-restricted therapeutics for diseases affecting or influenced by the human-microbial interface". This "later became the drug delivery technology [[DDS]]".